JP2024547218A - Ｉｇ様融合タンパク質およびその使用 - Google Patents

Ｉｇ様融合タンパク質およびその使用 Download PDF

Info

Publication number
JP2024547218A
JP2024547218A JP2024556825A JP2024556825A JP2024547218A JP 2024547218 A JP2024547218 A JP 2024547218A JP 2024556825 A JP2024556825 A JP 2024556825A JP 2024556825 A JP2024556825 A JP 2024556825A JP 2024547218 A JP2024547218 A JP 2024547218A
Authority
JP
Japan
Prior art keywords
fragment
domain
seq
polypeptide
dimerization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024556825A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024547218A5 (https=
JPWO2023112028A5 (https=
Inventor
オヴェド，クフィル
デンクバーグ，ガリット
リーフ，シャロン
ピンズール，エレナ
Original Assignee
キャノピー イムノ‐セラピューティクス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キャノピー イムノ‐セラピューティクス リミテッド filed Critical キャノピー イムノ‐セラピューティクス リミテッド
Publication of JP2024547218A publication Critical patent/JP2024547218A/ja
Publication of JP2024547218A5 publication Critical patent/JP2024547218A5/ja
Publication of JPWO2023112028A5 publication Critical patent/JPWO2023112028A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024556825A 2021-12-13 2022-12-13 Ｉｇ様融合タンパク質およびその使用 Pending JP2024547218A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163288782P 2021-12-13 2021-12-13
US63/288,782 2021-12-13
PCT/IL2022/051321 WO2023112028A1 (en) 2021-12-13 2022-12-13 Ig-like fusion proteins and use thereof

Publications (3)

Publication Number Publication Date
JP2024547218A true JP2024547218A (ja) 2024-12-26
JP2024547218A5 JP2024547218A5 (https=) 2025-12-23
JPWO2023112028A5 JPWO2023112028A5 (https=) 2025-12-23

Family

ID=86774007

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024556825A Pending JP2024547218A (ja) 2021-12-13 2022-12-13 Ｉｇ様融合タンパク質およびその使用

Country Status (6)

Country Link
US (1) US20250059255A1 (https=)
EP (1) EP4447993A4 (https=)
JP (1) JP2024547218A (https=)
CN (1) CN118678964A (https=)
CA (1) CA3240617A1 (https=)
WO (1) WO2023112028A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120500348A (zh) * 2022-12-13 2025-08-15 卡努佩免疫治疗公司 用于治疗重症肌无力的Ig样融合蛋白
WO2025030000A1 (en) * 2023-08-01 2025-02-06 Merida Biosciences, Inc. Molecules for controlling autoimmune response
AU2024318666A1 (en) * 2023-08-01 2026-01-22 Merida Biosciences, Inc. Molecules for controlling autoimmune response
WO2025126210A1 (en) * 2023-12-13 2025-06-19 Canopy Immuno-Therapeutics Ltd. Ig-like fusion proteins for treating musk myasthenia gravis
WO2025126216A1 (en) * 2023-12-13 2025-06-19 Canopy Immuno-Therapeutics Ltd. Improved acetylcholine receptor molecules and use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100719020B1 (ko) * 2005-09-28 2007-05-17 광주과학기술원 재조합 아세틸콜린 수용체 폴리펩티드, 폴리펩티드 유도체및 이를 유효성분으로 포함하는 중증근무력증 치료제
JP4857396B1 (ja) * 2011-04-13 2012-01-18 日本製薬株式会社 融合蛋白質
WO2016044137A2 (en) * 2014-09-15 2016-03-24 The Trustees Of The University Of Pennsylvania Acetylcholine receptor-specific immunosuppressive compositions and methods of treatment of myasthenia gravis

Also Published As

Publication number Publication date
WO2023112028A1 (en) 2023-06-22
EP4447993A1 (en) 2024-10-23
CA3240617A1 (en) 2023-06-22
EP4447993A4 (en) 2026-04-01
US20250059255A1 (en) 2025-02-20
CN118678964A (zh) 2024-09-20

Similar Documents

Publication Publication Date Title
US20250059255A1 (en) Ig-like fusion proteins and use thereof
JP7476298B2 (ja) Ｍａｇｅ－ａに特異的に結合する抗原結合タンパク質
ES2293748T3 (es) Moleculas de fijacion poliespecificas y usos de las mismas.
AU2017357944B2 (en) Activin receptor type IIa variants and methods of use thereof
CN111867612A (zh) 抗PDL1、IL-15和TGF-β受体组合分子
CN110799528A (zh) 基于多聚体il-15的分子
KR20200085832A (ko) 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법
CA3026652A1 (en) Anti-tnfrsf25 antibodies
WO2016081455A1 (en) Human tnfrsf25 antibody
US20250376502A1 (en) Ig-like fusion proteins for treating graves disease
KR20250166188A (ko) Tnfr2 결합 폴리펩타이드 및 이의 용도의 방법
JP2025541324A (ja) 重症筋無力症を治療するためのｉｇ様融合タンパク質
RU2652880C2 (ru) Антитело против рецептора эпидермального фактора роста
CN113164573B (zh) 包含修饰的MHC II类DRα1结构域的重组多肽及其应用方法
CN110577603B (zh) 一种抗cd3和抗cd19双特异性抗体
WO2025126210A1 (en) Ig-like fusion proteins for treating musk myasthenia gravis
CN109422814A (zh) 一种抗La/SSB嵌合体抗原修饰的NK细胞、其制备方法及其应用
WO2025126216A1 (en) Improved acetylcholine receptor molecules and use thereof
CN121443630A (zh) 用于治疗膜性肾病的ig样融合蛋白
EP4680630A1 (en) Ig-like fusion proteins for treating pemphigus vulgaris and foliaceus
WO2024231931A1 (en) Ig-like fusion proteins for treating immune thrombocytopenia
WO2025126202A1 (en) P32-specific antibodies and car t cells for the treatment of p32 expressing tumors
WO2025233431A1 (en) Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof
CA3235433A1 (en) Dual function antigen binding molecules
WO2024163723A9 (en) Molecules that bind to follistatin polypeptides

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251212